A 6-month open-label extension and 12-month follow-up in 781 women receiving full-length parathyroid hormone, PTH(1–84), has revealed the benefits of adherence to the daily injections. The participants had already received PTH(1–84) for 18 months; treatment over 24 months increased BMD at the lumbar spine by 6.8% above baseline. In those with ≥80% adherence to the regimen, however, the increase was 8.3%, as compared with 4.9% in patients with poor adherence. Correspondingly, fewer fractures were sustained by those with greater adherence.
ORIGINAL RESEARCH PAPER
Black, D. M. et al. Improved adherence with PTH(1–84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. Osteoporosis Int. doi:10.1007/s00198-012-2098-3
Rights and permissions
About this article
Cite this article
Stick with PTH therapy for postmenopausal osteoporosis. Nat Rev Rheumatol 8, 562 (2012). https://doi.org/10.1038/nrrheum.2012.162
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.162
